Overview
NGNE market data
Price History
NGNE price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.24 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.68 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -8,123.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $15.93 – $43.66 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $721.7M · P/B 1.20.
Company News
Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $166Benzinga · Aug 12, 2026, 3:53 PM
Guggenheim Maintains Buy on Neurogene, Raises Price Target to $81Benzinga · Aug 12, 2026, 12:31 PM
HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $65Benzinga · Aug 12, 2026, 11:40 AM
Neurogene Q2 EPS $(1.53) Misses $(1.39) EstimateBenzinga · Aug 11, 2026, 11:45 AM
8-K filing — Neurogene Inc. (NGNE)SEC EDGAR · Aug 11, 2026, 11:32 AM
Neurogene Prices $125M Public Offering At $30/Share, $29.999999 Pre‑Funded WarrantsBenzinga · Jul 1, 2026, 11:10 AM
Neurogene Reveals Proposed Public Offering; No Size DisclosedBenzinga · Jun 30, 2026, 8:05 PM
Neurogene Announces Updated Data From Phase 1/2 Clinical Trial Evaluating NGN-401 Gene Therapy For Treatment Of Females With Rett SyndromeBenzinga · Jun 29, 2026, 11:25 AM
Neurogene Completes Dosing In Embolden Registrational Trial Of NGN-401, Investigational Gene Therapy Designed To Be One-Time Treatment For Rett SyndromeBenzinga · Jun 8, 2026, 11:40 AM